Andrew Beale is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 13-day span, the pace is roughly 1.1 stories per week. They are less corroborated than the beat average, carrying 3 original sources each against 4.8 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Arete Research
Andrew Beale is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 13-day span, the pace is roughly 1.1 stories per week. They are less corroborated than the beat average, carrying 3 original sources each against 4.8 for the same window. aerospace accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Their average consequence score of 7 runs below the beat's 7.2 for that window. This profile follows 2 Space & Defense stories mentioning Arete Research across the period from June 21, 2026 to July 3, 2026.
Stories tracked
2
Per week
1.1
Sources per story
3
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 75 Space & Defense stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Arete Research. Shared-story counts are live from our verified record — not editorial picks.
With the IPO quiet period expiring on July 7, SpaceX will finally get analyst ratings just as Starship and StarlinkV3 move toward deployment. The most bullish call sees $401. For aerospace investors, the impending coverage wave will clarify whether the market is properly valuing the company’s next-generation space and satellite assets.
Arete Research’s $401 price target for SpaceX isn’t just a financial call—it’s a wager on Starship achieving commercial viability. Without that heavy-lift rocket, the Starlink V3 satellites that form the analyst’s thesis remain grounded, leaving the stock’s upside highly uncertain.